Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In June 2023, Merck announced the results of a Phase 2a clinical trial of efinopegdutide , a GLP-1 receptor/glucagon-like peptide-1 receptor dual agonist, for treating NASH
Contact your pharmacy immediately for a replacement
Wall Street analysts maintain a consensus hold rating, with an average price target around $48.57 implying about 34% upside from current levels
The potential of GLP-1 agonists in weight loss has been a topic of ongoing discussion, but FDA approval for obesity has only been granted in the past decade
This route enhances the peptide's bioavailability in investigational contexts, making it especially useful in experiments requiring consistent pharmacokinetic tracking over time
